- Home
- GLSI vs FENC Comparison
GLSI vs FENC Comparison
Compare GLSI & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLSI
- FENC
- Stock Information
- Founded
- GLSI 2006
- FENC 1996
- Country
- GLSI United States
- FENC United States
- Employees
- GLSI N/A
- FENC N/A
- Industry
- GLSI Biotechnology: Pharmaceutical Preparations
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GLSI Health Care
- FENC Health Care
- Exchange
- GLSI Nasdaq
- FENC Nasdaq
- Market Cap
- GLSI 143.4M
- FENC 156.9M
- IPO Year
- GLSI 2020
- FENC 2001
- Fundamental
- Price
- GLSI $12.87
- FENC $5.54
- Analyst Decision
- GLSI Strong Buy
- FENC Strong Buy
- Analyst Count
- GLSI 1
- FENC 2
- Target Price
- GLSI $38.00
- FENC $14.00
- AVG Volume (30 Days)
- GLSI 43.0K
- FENC 73.5K
- Earning Date
- GLSI 11-14-2024
- FENC 11-07-2024
- Dividend Yield
- GLSI N/A
- FENC N/A
- EPS Growth
- GLSI N/A
- FENC N/A
- EPS
- GLSI N/A
- FENC N/A
- Revenue
- GLSI N/A
- FENC $49,348,000.00
- Revenue This Year
- GLSI N/A
- FENC $170.43
- Revenue Next Year
- GLSI N/A
- FENC $6.70
- P/E Ratio
- GLSI N/A
- FENC N/A
- Revenue Growth
- GLSI N/A
- FENC 278.09
- 52 Week Low
- GLSI $8.00
- FENC $3.96
- 52 Week High
- GLSI $21.44
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- GLSI 51.89
- FENC 40.02
- Support Level
- GLSI $11.50
- FENC $5.61
- Resistance Level
- GLSI $12.84
- FENC $6.19
- Average True Range (ATR)
- GLSI 0.90
- FENC 0.26
- MACD
- GLSI 0.09
- FENC -0.10
- Stochastic Oscillator
- GLSI 59.49
- FENC 6.42
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells to inhibit the spread of cancer.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.